Showing 241–260 of 18,047 drug recalls
Drug Recall
Ongoing
2026 record Class II
Gasco Isopropyl Alcohol 70%, Net Contents: 16 Oz. (474 mL). Manufactured by: Gasco Industrial Corp., PO Box 1360 Gurabo PR 00778 Made in USA UPC 7 87302 13044 3 by Gasco Industrial Corp.
Reason
Subpotent drug Recall initiated
May 29, 2026 Reported by FDA
July 15, 2026 Distribution
Nationwide within the US
View recall →
Drug Recall
Ongoing
2026 record Class II
Methohexital Sodium, 100 mg/10 mL (10 mg/mL), Total Volume: 10 mL, Rx only, Compounded drug, QuVa Pharma, 1075 W Park One Dr, Suite 100, Sugar Land, TX 77478, Product code: 70092-1310-46. by QuVa Pharma, Inc.
Reason
Failed Impurities/Degradation Specifications Recall initiated
June 24, 2026 Reported by FDA
July 15, 2026 Distribution
Nationwide within the United States
View recall →
Drug Recall
Ongoing
2026 record Class II
Medline Remedy Specialized Silicone Cream (Hydraguard-D ),Manufactured for Medline Industries, LP, Three Lakes Drive, Northfield, IL 80090 2 FL OZ (59 mL) NDC 53329-159-13 4 FL OZ (118 mL) NDC 53329-159-04 by BioMed Laboratories, LLC.
Reason
Failed Impurities/Degradation Specifications; Formaldehyde levels exceeded specification. Recall initiated
June 11, 2026 Reported by FDA
July 15, 2026 Distribution
Nationwide in the US
View recall →
Drug Recall
Ongoing
2026 record Class II
Methohexital Sodium for Injection, USP 500 mg Multiple Dose Vial, Rx Only, Manufactured by: OneSource Specialty, Pharma Limited, Bengaluru - 561 203, India, Manufactured for: Avet Pharmaceuticals Inc., East Brunswick, NJ 08816, NDC 23155-893-31 by ONESOURCE SPECIALTY PHARMA LIMITED
Reason
Failed Impurities/Degradation Specifications Recall initiated
June 7, 2026 Reported by FDA
July 15, 2026 Distribution
Nationwide within the United States
View recall →
Drug Recall
Ongoing
2026 record Class II
Glucagon Emergency Kit for Low Blood Sugar, Glucagon for Injection USP, 1mg per vial, Diluent for Glucagon, 1 mL syringe, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Naples, FL 34108, Manufactured by: Lupin Limited, Nagpur - 441108, INDIA, NDC 70748-311-01 by Lupin Pharmaceuticals Inc.
Reason
CGMP deviation: OOS result observed for the Gliding Force functionality test during 12-month long term stability testing. Recall initiated
June 23, 2026 Reported by FDA
July 8, 2026 Distribution
Nationwide within the U.S.
View recall →
Drug Recall
Ongoing
2026 record Class II
Gemcitabine Injection, 1 g per 26.3 mL (38 mg/mL), 26.3 mL Single-Dose Vial, For Intravenous Infusion ONLY, Rx only, Manufactured by: THYMOORGAN PHARMAZIE GmbH, Schiffgraben 23, 38690 Goslar, Germany; Distributed by: Hikma, Berkeley Heights, NJ 07922. NDC: 0143-9341-01 by McKesson
Reason
Temperature Abuse: Product was stored incorrectly in a controlled room temperature environment instead of a refrigerated environment. Recall initiated
June 10, 2026 Reported by FDA
July 8, 2026 Distribution
Nationwide within the United States
View recall →
Drug Recall
Ongoing
2026 record Class II
Revitaderm Wound Care, First Aid Antiseptic Gel, Benzalkonium Chloride 0.1%) packaged as (a) 1.0 Fl OZ (16 mL) bottle, long pointy cap, NDC 63347-120-02; (b) 3.0 Fl OZ (85 g) tube, with short twist cap, NDC 63347-120-01; Manufactured By: Blaine Labs, Inc. 11037 Lockport Place, Santa Fe Springs, CA 90670, by Blaine Labs Inc
Reason
CGMP Deviations; product manufactured in the same facility under the same conditions as the product found to be contaminated Recall initiated
April 8, 2026 Reported by FDA
July 8, 2026 Distribution
Nationwide in the USA
View recall →
Drug Recall
Ongoing
2026 record Class II
Fungal Fusion ERADICATION Solution, Antifungal & Antimicrobial Kit. Contains, 1x2 oz bottle Fungal Fusion Antifungal (Miconazole Nitrate) Cream, 1x2oz bottle Fungal Fusion Antifungal Solution (25% Undecylenic Acid) and 1x1oz bottle of Fungal Fusion Eradication Antimicrobial Show Spray (isopropyl Alcohol, D-Limonene, Undecylenic Acid). Manufactured By: Blaine Labs, Inc., 11037 Lockport Place, Santa Fe Springs, CA 90670, Manufactured for Doctor's Inc by Blaine Labs Inc
Reason
CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry Recall initiated
April 8, 2026 Reported by FDA
July 8, 2026 Distribution
Nationwide in the USA
View recall →
Drug Recall
Ongoing
2026 record Class II
TERPENICOL Antifungal Solution, (Undecylenic (10-Undecenoic) acid 25%), 1.0 Fl Oz (29.6 mL), Manufactured By: Blaine Labs, Inc., 11037 Lockport Place, Santa Fe Springs, CA 90670. NDC 63347-600-01 by Blaine Labs Inc
Reason
CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry Recall initiated
April 8, 2026 Reported by FDA
July 8, 2026 Distribution
Nationwide in the USA
View recall →
Drug Recall
Ongoing
2026 record Class II
vite20 Antifungal Cream, (10% Undecylenic Acid), 0.54 OZ (15 g) bottle, Manufactured By: Blaine Labs, Inc., 11037 Lockport Place, Sante Fe Springs, CA 90670, UPC 6 16728 00039 2. by Blaine Labs Inc
Reason
CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry Recall initiated
April 8, 2026 Reported by FDA
July 8, 2026 Distribution
Nationwide in the USA
View recall →
Drug Recall
Ongoing
2026 record Class II
TERPENICOL Antifungal Cream (Undecylenic Acid 13%), 1.0 oz (28 g) bottles, Manufactured By: Blaine Labs, Inc., 11037 Lockport Place, Sante Fe Springs, CA 90670, NDC 63347-601-01. by Blaine Labs Inc
Reason
CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry Recall initiated
April 8, 2026 Reported by FDA
July 8, 2026 Distribution
Nationwide in the USA
View recall →
Drug Recall
Ongoing
2026 record Class II
TRIPENICOL S Antifungal Solution (Undecylenic Acid 25%), 1.25 FL OZ (37.5 mL) bottle, Manufactured For: Trifluent Pharma, LLC, San Antonio, TX 78213, NDC 73352-550-01. by Blaine Labs Inc
Reason
CGMP Deviations; the firm discontinued required stability testing for products on the market still within expiry Recall initiated
April 8, 2026 Reported by FDA
July 8, 2026 Distribution
Nationwide in the USA
View recall →
Drug Recall
Ongoing
2026 record Class II
TRIFLUENT PHARMA TRIDERGEL Wound Care Gel, (Benzalkonium Chloride 0.1%), 1.0 fl oz, (29.6 mL) bottle with long pointy cap, Manufactured for: Trifluent Pharma, LLC. San Antonio, TX 78213. NDC 73352-520-01. by Blaine Labs Inc
Reason
CGMP Deviations: product manufactured in the same facility under the same conditions as the product found to be contaminated Recall initiated
April 8, 2026 Reported by FDA
July 8, 2026 Distribution
Nationwide in the USA
View recall →
Drug Recall
Ongoing
2026 record Class I
Revitaderm Wound Care Gel, Benzalkonium Chloride 0.1%, packaged in 1.0 FL OZ (37 mL) bottle, shorter twist cap, Manufactured By: Blaine Labs, Inc. 11037 Lockport Place Santa Fe Springs, CA 90670, NDC 63347-120-02. by Blaine Labs Inc
Reason
Microbial contamination of Non-Sterile Product: samples identified the presence of Lysinibacillus fusiformis and other Bacillus spp Recall initiated
April 8, 2026 Reported by FDA
July 8, 2026 Distribution
Nationwide in the USA
View recall →
Drug Recall
Ongoing
2026 record Class II
Cinacalcet Hydrochloride Tablets, 90 mg, 30-count bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-412-02 by Cipla USA, Inc.
Reason
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). Recall initiated
June 29, 2026 Reported by FDA
July 8, 2026 Distribution
USA Nationwide
View recall →
Drug Recall
Ongoing
2026 record Class II
Cinacalcet Hydrochloride Tablets, 60 mg, 30-count bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-411-02 by Cipla USA, Inc.
Reason
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). Recall initiated
June 29, 2026 Reported by FDA
July 8, 2026 Distribution
USA Nationwide
View recall →
Drug Recall
Ongoing
2026 record Class II
Cinacalcet Hydrochloride Tablets, 30 mg, 30-count bottle, Rx Only, Manufactured by: Cipla Ltd., MIDC, Patalganga, India; Manufactured for: Cipla USA, Inc., 10 Independence Boulevard, Suite 300, Warren, NJ 07059, NDC 69097-410-02 by Cipla USA, Inc.
Reason
cGMP Deviations: presence of N-nitroso-cinacalcet, above the acceptable daily intake (ADI). Recall initiated
June 29, 2026 Reported by FDA
July 8, 2026 Distribution
USA Nationwide
View recall →
Drug Recall
Ongoing
2026 record Class II
Dextroamphetamine Saccharate, Amphetamine Aspartate Monohydrate, Dextroamphetamine Sulfate and Amphetamine Sulfate Extended-Release Capsules, 5 mg, Rx Only, 100 capsules, Distributed by: Lannett Company, Inc., Philadelphia, PA 19136, NDC: 0527-0790-37. by Lannett Company Inc.
Reason
Labeling: Label Mix-up: Capsules contain only immediate-release (IR) pellets while labeled as ER capsules. Recall initiated
June 26, 2026 Reported by FDA
July 8, 2026 Distribution
US Nationwide.
View recall →
Drug Recall
Ongoing
2026 record Class II
Lidocaine HCl Injection USP, 1% (10 mg/mL), 5 mL single dose ampule, Rx Only, Distributed by Enovachem Pharmaceuticals, Torrance, CA 90501, NDC: 85766-187-01. by Asclemed USA Inc.
Reason
Lack of Assurance of Sterility Recall initiated
June 8, 2026 Reported by FDA
July 8, 2026 Distribution
USA Nationwide
View recall →
Drug Recall
Ongoing
2026 record Class II
Accucaine, Kit contains: Lidocaine HCl Injection USP, 1% (10 mg/mL), 5 mL single dose ampule, Rx Only, Distributed by Enovachem Pharmaceuticals, Torrance, CA 90501, NDC: 76420-715-01. by Asclemed USA Inc.
Reason
Lack of Assurance of Sterility Recall initiated
June 8, 2026 Reported by FDA
July 8, 2026 Distribution
USA Nationwide
View recall →
Data last updated: October 29, 2026 ET
This information is republished from FDA's Recall Enterprise System through openFDA. Public Health Trace
does not verify or supplement it, is not affiliated with the FDA, and does not provide medical advice --
always follow the guidance of your pharmacist, physician, or the recalling company for any medication you take.
Read the full medical disclaimer .
